For the first time in Australia, a major new cancer treatment drug is being given to patients at Cabrini.
The drug, FN-1501, is a targeted therapy, and an important breakthrough in cancer treatment. It is hoped to dramatically improve results and is expected to be tolerated much better than existing forms of chemotherapy. This is only the second time in the world the drug has been used and the first time it has been used in Australia.
Cabrini researchers have been closely involved in the development of this new drug, and Cabrini has been selected as a research centre of excellence. Professor Gary Richardson, Head of Cabrini’s Department of Medical Oncology, who worked with researchers to develop the drug, said it was part of a phase one clinical trial designed to evaluate the safety, tolerability, and anti-tumour activity of the drug in patients who have advanced solid tumours.
“We have high hopes for this new drug, which has shown very promising results in a range of cancers in animals. We expect the drug will be tolerated much more readily by patients. We also expect it to combat tumours more effectively than traditional chemotherapy. The drug is designed to block cell tumour proliferation, thus killing cancer cells.” - said Professor Richardson
Targeted cancer therapies
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules, called molecular targets, that are involved in the growth, progression, and spread of cancer. Targeted cancer therapies are sometimes called molecularly targeted drugs, molecularly targeted therapies, precision medicines, or similar names.
Targeted therapies are currently the focus of anti-cancer drug development. They are a cornerstone of precision medicine, a form of medicine that uses information about a person’s genes and proteins to prevent, diagnose, and treat disease.
Patients interested in joining the clinical trial for this drug at Cabrini can find out more at www.cabrini.com.au/cancertrials